Clinical Trials Sponsored by Unipharm, Inc.

Total 35432 results

Unipharm, Inc.

Completed

Efficacy and Safety of ARTRA (Glucosamine Plus Chondroitin Sulfate Combination) in Treatment of Chronic Low Back Pain

Low Back Pain

Russian Federation
Navitas Pharma
IndiPharm Inc.

Not yet recruiting

Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium (CHAMP)

Diabetes | Hyponatremia | Arterial Hypertension | Hypokalemia
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed Conditions

To Determine Bioequivalence Under Fed Conditions

Canada
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions

Canada
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioavailability Study of Torsemide Tablets Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioequivalence Study Doxycycline Tablets and Monodox Capsules Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions

Canada
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions

Canada
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fed Conditions

To Determine Bioequivalence Under Fed Conditions

Canada
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions

To Determine Bioequivalence Under Fed Conditions

Canada
Ionis Pharmaceuticals, Inc.
Anapharm

Completed

Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers

Inflammatory Diseases

Canada
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioavailability Study of Torsemide Tablets Under Fed Conditions

Healthy
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions

Canada
Par Pharmaceutical, Inc.
SFBC Anapharm

Completed

Bioavailability Study of Propranolol Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions

Canada
Par Pharmaceutical, Inc.
SFBC Anapharm

Completed

Bioavailability Study of Propranolol Under Fed Conditions

To Determine Bioequivalence Under Fed Conditions
InQpharm Group

Completed

Efficacy and Safety of Glucosanol™ in Body Weight Reduction

Overweight and Obesity

Germany
SciPharm SàRL

Completed

Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH) (CTREPH)

Non-operable Chronic Thromboembolic Pulmonary Hypertension

Austria, Poland, Czechia, Germany
InQpharm Group

Withdrawn

Tolerability and Benefit of IQP-AS-121 on Fatigue and Mental Alertness

Fatigue

Germany
InQpharm Group

Completed

Clinical Benefit of a Mouthrinse for the Treatment of Dentine Hypersensitivity

Dentin Sensitivity

Germany
InQpharm Group

Completed

Benefit and Tolerability of IQP-AE-103 in Weight Loss

Obesity | Overweight

Germany
InQpharm Group

Completed

Efficacy and Safety of IQP-AK-102 in Reducing Appetite

Appetite Regulation | Energy Intake | Appetite Suppression

Germany
InQpharm Group

Completed

Efficacy and Safety of Glucosanol in Maintaining Body Weight

Obesity | Overweight

Germany
InQpharm Group

Completed

Safety and Efficacy of Litramine in Overweight and Obese Subjects

Obesity | Overweight | Weight Loss

Germany
Nuvamid SA
Medpace, Inc.; Anapharm; LGD

Active, not recruiting

Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants

Healthy Volunteers

United States
InQpharm Group

Completed

Benefit and Tolerability of IQP-LU-104 in Weight Loss

Obesity | Overweight

Germany
InQpharm Group

Completed

Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea

Diarrhoea

Germany
InQpharm Group

Completed

Efficacy and Safety of Litramine in 1 Year Weight Loss Study

Weight Loss | Overweight and Obesity | Obesity; Excess Calories

Germany
InQpharm Group

Completed

Influence of IQPAS-119 on Post-Marathon Susceptibility to Infections and Others

Upper Respiratory Tract Symptoms

Germany
InQpharm Group

Completed

Efficacy and Safety of IQP-VV-102 in Weight Management

Obesity | Overweight

Germany
InQpharm Group

Completed

Litramine in Weight Maintenance

Overweight | Obese | Weight Maintenance

Germany
InQpharm Group

Completed

IQP-CL-101 in IBS Management

Irritable Bowel Syndrome

Germany
InQpharm Group

Completed

IQP-PO-101 for the Regulation of Bowel Movement Frequency

Constipation | Irregular Bowel Movement Frequency

Germany
InQpharm Group

Completed

Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn

Postprandial Heartburn

Germany
Inipharm Australia Pty Ltd

Recruiting

A Study of INI-822 in Healthy Volunteers and Participants With Non-alcoholic Steatohepatitis (NASH) or Presumed NASH

Non-alcoholic Steatohepatitis

Australia
Par Pharmaceutical, Inc.
Covance; SFBC Anapharm

Terminated

Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension

Healthy

United States
InQpharm Group

Withdrawn

Vasoactive Effects of IQP-AS-118 in Healthy Individuals

Cardiovascular Disease | Blood Flow

Germany
InQpharm Group

Completed

Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol

Blood Pressure | Low Density Lipoprotein Cholesterol Level

Germany
InQpharm Group

Completed

Efficacy of Glucosanol™ in Reducing Post-prandial Glucose Levels in Overweight Subjects

Hyperglycemia, Postprandial

Germany
InQpharm Group

Completed

Safety and Efficacy of IQP- AK-102 in Reducing Body Weight

Weight Loss

Germany
InQpharm Group

Terminated

Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections

Common Cold | Upper Respiratory Tract Infections

Germany
InQpharm Group

Completed

Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects

Hyperglycemia | Prediabetes

Germany
InQpharm Group

Completed

Litramine for Weight Loss

Weight Loss
InQpharm Group

Completed

Efficacy and Safety of Zenoctil in Reducing Body Weight

Overweight

Germany
InQpharm Group

Completed

Safety and Efficacy of IQP-AK-102 in Reducing Appetite

Weight Loss | Appetite Modulation (Focus of Study)

Germany
InQpharm Group

Completed

Safety and Efficacy of Glucosanol in Reducing Body Weight in Overweight and Obese Subjects

Overweight and Obesity

Germany
InQpharm Group

Completed

Nasya in Allergic Rhinitis

Allergic Rhinitis

Germany
InQpharm Group

Completed

Effect of Litramine on Fat Excretion

Healthy Subjects

Germany
AMIpharm Co., Ltd.

Completed

Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area

Moderate or Severe Submental Fullness

Korea, Republic of
AMIpharm Co., Ltd.

Recruiting

Evaluate the Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Chin Area

Healthy

Korea, Republic of
AMIpharm Co., Ltd.

Completed

Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects

Healthy Subjects | Submental Fat

Korea, Republic of
AMIpharm Co., Ltd.

Completed

Evaluate the Efficacy and Safety of Polyene Phosphatidylcholine Injection (AYP-101) for the Reduction of Submental Fat (AYP-101)

Moderate or Severe Submental Fullness

Korea, Republic of

Clinical Trials Sponsored by Unipharm, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations